Sleeplessness: Insomnia and the Overactive Brain

What it is

Insomnia is difficulty falling asleep, staying asleep, or waking too early, despite adequate opportunity to sleep, with consequences felt during the day — fatigue, low mood, poor concentration, irritability. That last qualifier matters: someone who sleeps little because they choose to stay up does not have insomnia; insomnia is the frustrating experience of being unable to sleep when one is trying to. When the problem occurs at least three nights a week for three months or more, it is recognized as a disorder in its own right rather than a passing disturbance. Insomnia is the most common sleep complaint and one of the most common health complaints of any kind, and the way to understand it — and treat it well — runs counter to most people's intuitions.

Subtypes and specifications

Insomnia is described first by when in the night it strikes: sleep-onset (trouble falling asleep), sleep-maintenance (waking during the night and struggling to return), and early-morning awakening (waking far too early). It is also divided into acute insomnia, triggered by an identifiable stressor and usually self-limiting, and chronic insomnia, which has taken on a life of its own.

A key modern correction concerns the old idea of "primary" versus "secondary" insomnia. Most chronic insomnia occurs alongside another condition — depression, anxiety, chronic pain — but it is now understood as typically a distinct, bidirectional problem rather than a mere symptom that will vanish once the "real" disorder is treated. Insomnia both results from and worsens these conditions, and it usually needs to be treated directly. Researchers also distinguish a more biologically severe phenotype — insomnia with objectively short sleep, linked to greater cardiometabolic risk — from insomnia with relatively preserved sleep duration, which is more closely tied to psychological arousal and misperception of sleep.

The neurobiology: hyperarousal

The central insight of modern sleep science is that chronic insomnia is best understood as a disorder of hyperarousal — the brain's wake-promoting systems are running too hot, not only at night but around the clock. People with insomnia show elevated stress-hormone (cortisol) output, a faster metabolic rate, increased high-frequency electrical activity in the brain at the moment of trying to sleep, and heightened sympathetic "fight-or-flight" tone. The problem is less an absence of sleepiness than an excess of wakefulness.

This makes sense against the basic architecture of sleep. Two processes normally govern it: a homeostatic sleep pressure that builds the longer we are awake (driven by the accumulation of adenosine), and a circadian clock that times sleep to night. Acting on these is a wake–sleep switch built from mutually opposing systems — wake-promoting networks using orexin (also called hypocretin), histamine, and norepinephrine, opposed by sleep-promoting networks using GABA and adenosine. Orexin in particular stabilizes wakefulness. In insomnia, this switch is biased toward "on."

Layered on top of the biology is conditioned and cognitive arousal. A useful framework (the "3 P" model) distinguishes predisposing traits, a precipitating stressor, and — most important for chronic insomnia — perpetuating factors: worry about sleep, clock-watching, and spending excessive time in bed, which train the brain to associate the bed with wakeful struggle. These learned, self-reinforcing patterns are why insomnia outlasts the stress that started it, and they are precisely what effective treatment targets.

Why it matters

Insomnia is not a trivial nuisance. Prospective studies show it is a robust predictor of new-onset depression — sleeplessness often precedes the mood disorder rather than merely accompanying it — and it is linked to anxiety, suicide risk, relapse, and, in the short-sleep phenotype, cardiometabolic disease. Treating insomnia can improve depression outcomes, which is one reason it deserves direct attention rather than being waved off as a side issue.

Treatment

Here is where intuition misleads most people, who reach first for a pill. The evidence points elsewhere.

Digital and app-based CBT-I has made this approach far more accessible.

Medications have a real but secondary role, mainly for short-term use or when CBT-I is unavailable or insufficient. The older benzodiazepines and "Z-drugs" (such as zolpidem) enhance GABA signaling and work in the short term but carry tolerance, dependence, next-day impairment, and fall risk, and are not meant for indefinite use. The newer orexin-receptor antagonists (suvorexant, lemborexant, daridorexant) are mechanistically elegant — they dial down the overactive wake signal rather than broadly sedating — and tend to carry less dependence risk. Low-dose doxepin is approved for sleep maintenance, trazodone is widely used off-label with modest evidence, and melatonin and its agonists help mainly with sleep timing. Sedating antihistamines and antipsychotics such as quetiapine are commonly misused for sleep and are generally not recommended — the antihistamines for tolerance and anticholinergic effects, quetiapine for its metabolic risks.

The honest picture is a striking mismatch: the first-line treatment (CBT-I) is underused, while sedative medications are overused, often long past the point where they help.

How it connects

Sleeplessness is woven through this library. Its hyperarousal mechanism overlaps with the chronic stress and HPA-axis account; its bidirectional relationship with mood ties it to the sleep and circadian etiology; its treatments connect to GABAergic and orexin pharmacology; and it must be carefully distinguished from the daytime fatigue it produces — sleeplessness is a problem of too much wakefulness, while fatigue can occur with perfectly adequate sleep.

Caveats

Sleep need varies widely between individuals, so insomnia is defined by a distressing change and daytime impairment, not by hitting a fixed number of hours. Sleep hygiene advice alone is a common and inadequate prescription. Hypnotic medications invite dependence and tend to outstay their usefulness. And insomnia occurring alongside another condition deserves its own treatment rather than being dismissed as a symptom that will resolve on its own.

Bottom line

Insomnia is the experience of being unable to sleep despite the chance to — best understood not as too little sleepiness but as too much wakefulness, an overactive arousal system maintained by stress, biology, and learned habits of worry around the bed. It matters because it predicts and worsens depression and other illness, and it is eminently treatable — but by the route most people overlook. The first-line treatment is a behavioral therapy, CBT-I, which retrains the system that has gone awry; medications, especially the newer orexin-targeting agents, play a supporting and mostly short-term role. The most valuable correction to common belief is simple: for lasting relief from chronic sleeplessness, skills beat sedatives.

Selected references

1. Riemann D, et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev. 2010.
2. Vgontzas AN, et al. Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev. 2013.
3. Saper CB, Fuller PM, et al. Sleep state switching. Neuron. 2010.
4. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987.
5. Buysse DJ. Insomnia. JAMA. 2013.
6. Morin CM, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009.
7. Trauer JM, et al. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015.
8. Qaseem A, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016.
9. Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an AASM clinical practice guideline. J Clin Sleep Med. 2021.
10. Baglioni C, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011.
11. Mignot E, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two randomised, double-blind, placebo-controlled phase 3 trials. Lancet Neurol. 2022.
12. Krystal AD, et al. The assessment and management of insomnia: an update. World Psychiatry. 2019.
13. Espie CA, et al. Digital cognitive behavioural therapy for insomnia: a randomized clinical trial. JAMA Psychiatry. 2019.
14. Wilson S, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. J Psychopharmacol. 2019.
15. Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010.
16. Sateia MJ, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults (AASM). J Clin Sleep Med. 2017.